Aquestive Therapeutics CEO Barber Daniel Sells 400 Shares for $2.4M on 2025-09-19.

Aquestive Therapeutics, Inc. (AQST) has announced that Director, President, and CEO Daniel Barber has sold 400 shares at a price of $6 per share on September 19, 2025.

Aquestive Therapeutics, Inc. (AQST) has experienced a significant shift in its shareholder dynamics with the recent sale of 400 shares by Director, President, and CEO Daniel Barber. The transaction, which occurred on September 19, 2025, saw Barber sell the shares at a price of $6 per share. This sale comes amidst a period of notable analyst optimism and regulatory progress for the company.

As of the latest data, AQST's shares are trading at $5.67, marking a substantial 14.8% increase from recent levels Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of ^[1]. The company's consensus recommendation among analysts is a "Buy" rating, with seven analysts rating it as a "Buy" and one issuing a "Strong Buy" rating Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of ^[1]. The average 1-year price target for AQST is $10.2857, reflecting a robust market expectation for the company's future performance Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of ^[1].

One of the key drivers behind this optimism is the company's ongoing regulatory progress. In September 2025, the FDA waived the advisory committee meeting for AQST's New Drug Application for Anaphylm, a needle-free, orally delivered epinephrine film for severe allergic reactions Aquestive Therapeutics (AQST) Is Up 12.3% After FDA Waives Panel for Oral Epinephrine Application^[2]. This development significantly reduces regulatory risk and sets a January 31, 2026, approval decision date, potentially reshaping emergency allergy treatment options.

Despite the positive regulatory news, investors should be cautious about the challenges that lie ahead. The recent follow-on equity offering raised $85 million, which, while providing liquidity and runway for commercial preparations, also diluted existing shareholders Aquestive Therapeutics (AQST) Is Up 12.3% After FDA Waives Panel for Oral Epinephrine Application^[2]. The success of Anaphylm will hinge on its commercial acceptance and payer coverage, which remain significant uncertainties.

Institutional ownership in AQST stands at 32.45%, with several funds recently increasing their stakes in the company Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of ^[1]. Geode Capital Management LLC, for instance, lifted its stake by 16.2% in the second quarter, now owning 1,977,000 shares worth $6.545 million Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of ^[1]. These institutional inflows underscore the confidence in AQST's prospects, despite the recent insider selling.

In summary, the sale of 400 shares by Daniel Barber is a notable event amidst a period of strong analyst sentiment and regulatory momentum. While the company faces challenges in commercializing its new product, the overall market outlook remains positive, driven by the potential of Anaphylm and institutional support.